Rhythm Pharmaceuticals (RYTM) Non-Current Assets (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Non-Current Assets data on file, last reported at $12.2 million in Q1 2026.

• On a quarterly basis, Non-Current Assets fell 29.72% year-over-year to $12.2 million in Q1 2026; TTM through Mar 2026 was $49.6 million, a 40.33% decrease from a year earlier, with the FY2025 full-year figure at $13.3 million, down 26.52% from the prior year.
• Non-Current Assets for Q1 2026 stood at $12.2 million, down from $13.3 million in the prior quarter.
• Over the last five years, Non-Current Assets for RYTM reached as high as $31.4 million in Q1 2022 and fell as low as $12.1 million in Q2 2025.
• Historically, Non-Current Assets has averaged $22.0 million across 5 years, with a median of $24.5 million in 2023.
• Across the five-year window, Non-Current Assets soared 211.41% in 2022 and tumbled 50.76% in 2025, its largest moves.
• Year by year, Non-Current Assets stood at $28.2 million in 2022, then decreased by 13.34% to $24.5 million in 2023, then fell by 26.16% to $18.1 million in 2024, then declined by 26.52% to $13.3 million in 2025, then declined by 7.94% to $12.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $12.2 million in Q1 2026, $13.3 million in Q4 2025, and $12.1 million in Q3 2025.